News

News

  • December 1, 2025 Notice: Tokyo Head Office to be Relocated pdf （642KB）
  • November 20, 2025 Anti-CD19 monoclonal antibody UPLIZNAⓇ for I.V. Infusion 100mg Approval for additional indication of suppression of relapse of immunoglobulin G4-related disease in Japan ～Japan’s First Drug Approved for IgG4-Related Disease～ pdf （573KB）
  • November 5, 2025 Pipeline ― State of New Product Development
  • November 4, 2025 Launch of Tanabe Pharma’s Teaser Website
  • October 31, 2025 Official Approval of Company Name Change to “Tanabe Pharma” pdf （177KB）
  • October 23, 2025 Receipt of Complete Response Letter from U.S. FDA for investigational ND0612 pdf （199KB）
  • October 20, 2025 Announcement of Personnel Changes pdf （413KB）
  • October 14, 2025 Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of generalized Myasthenia Gravis in Japan pdf （582KB）
  • September 22, 2025 Announcement of Organizational Changes and Personnel Change pdf （246KB）
  • September 16, 2025 Expiration of Co-Promition Agreement for STELARA® (ustekinumab) pdf （265KB）
  • September 2, 2025 Announcement of launch of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug " CANALIA® Combination OD Tablets " ～Adoption of a printing design with enhanced identifiability and visibility～ pdf （255KB）
  • August 29, 2025 Change in Representative Director, New Executive Team and Management Structure pdf （417KB）
  • August 1, 2025 Pipeline ― State of New Product Development
  • July 10, 2025 To initiate joint research aiming to create innovative cancer drugs in Targeted Alpha Therapy pdf （458KB）
  • July 1, 2025 Mitsubishi Tanabe Pharma to Begin a New Chapter under Bain Capital Ownership -Company Name Change to “Tanabe Pharma Corporation” Effective December 1, 2025- pdf （248KB）
  • July 1, 2025 Appointment of Directors and Executive Officers pdf （203KB）
  • June 13, 2025 Initiation of Phase 1/2 clinical trial of MT-4561 for Advanced Solid Tumors pdf （266KB）
  • May 29, 2025 U.S. FDA Accepts Resubmission for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease pdf （205KB）
  • May 27, 2025 Launch of Radicava® for the Treatment of ALS in Australia pdf （170KB）
  • May 26, 2025 Announcement of Personnel Changes pdf （243KB）
  • May 20, 2025 Appointment of Directors pdf （155KB）
  • May 13, 2025 Pipeline ― State of New Product Development
  • May 9, 2025 CANAGLU Tablets 100mg, a sodium glucose co-transporter 2 (SGLT2) inhibitor in Thailand Mitsubishi Tanabe Pharma Thailand now started marketing pdf （357KB）
  • March 21, 2025 Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of immunoglobulin G4-related disease in Japan pdf （436KB）
  • March 19, 2025 Announcement of NHI Price Listing and Release Date of “Zepbound®”, a Long-Acting GIP/GLP-1 Receptor Agonist, for the Chronic Disease of “Obesity Disease” with Multiple Factors pdf （435KB）
  • March 13, 2025 Filling for a Oral Edaravone Formulation for the treatment of ALS in Korea pdf （174KB）
  • February 28, 2025 Regulatory Approval of Cariprazine (MP-214) For Adjunctive therapy for major depressive disorder in Thailand pdf （339KB）
  • February 21, 2025 EMA Accepts Marketing Authorization Application for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease pdf （223KB）
  • February 20, 2025 Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group
  • February 17, 2025 Additional Approval of Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug ~ First OD Tablets of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug in Japan ~ pdf （265KB）
  • February 7, 2025 Notice Concerning the Transfer of Mitsubishi Tanabe Pharma Corporation and its Subsidiaries
  • February 6, 2025 Pipeline ― State of New Product Development
  • January 7, 2025 Sub-licensing Agreement for the Oral Spleen Tyrosine Inhibitor Fostamatinib in Taiwan with Kissei Pharmaceutical pdf （316KB）
  • December 27, 2024 "Zepbound®", a Long-Acting GIP/GLP-1 Receptor Agonist, Approved for the Chronic Disease of "Obesity Disease" with Multiple Factors
  • December 12, 2024 Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group
  • December 5, 2024 Mitsubishi Tanabe Pharma Corporation Entered into Research Collaboration with Dewpoint to Advance Small Molecule Condensate Modulator for ALS
  • November 29, 2024 Sustainability Information
  • November 1, 2024 Pipeline ― State of New Product Development
  • November 1, 2024 Update on U.S. Development Plan of Investigational ND0612 for the Treatment of Motor Fluctuations in People with Parkinson’s Disease
  • August 23, 2024 Termination of Exclusive Sales Rights Agreements for HGF Gene Therapy Product "Collategene®" in Japan and the US
  • August 1, 2024 Pipeline ― State of New Product Development
  • July 29, 2024 Notice Regarding Implementation of Voluntary Retirement Program
  • July 9, 2024 Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
  • June 24, 2024 Distribution Discontinuation of HGF gene therapy product "Collategene®", following withdrawal of the manufacturing and marketing approval application
  • June 17, 2024 Transfer of Argatroban Business in Europe
  • June 11, 2024 Receipt of Complete Response Letter from U.S. FDA for ND0612
  • May 22, 2024 Announcement of launch of SGLT2 inhibitor "CANAGLU® OD Tablets" ～Adoption of Environmentally Friendly Biomass-plastic PTP Sheets～
  • May 22, 2024 Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan-World-first cream-type allergic conjunctivitis treatment requiring just once daily administration to the upper and lower eyelids-
  • May 15, 2024 Pipeline ― State of New Product Development
  • May 9, 2024 The Global Health Innovative Technology Fund provides grant to Mitsubishi Tanabe Pharma and DNDi for Chagas disease drug discovery
  • May 8, 2024 Announcement of Approval Submission and Marketing Alliance in Japan for Tirzepatide as a Drug for Obesity Disease
  • May 7, 2024 Santen and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis
  • April 9, 2024 RADICAVA ORS® as Orphan drug designation and approval in US
  • March 19, 2024 Announcement of Publication in The Lancet Neurology from the Clinical Study of Investigational ND0612 for Parkinson's Disease
  • March 18, 2024 Additional Approval of SGLT2 inhibitor CANAGLU® OD Tablets～First OD Tablets of SGLT2 inhibitors in Japan～
  • March 15, 2024 Launch of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
  • March 4, 2024 Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets
  • February 27, 2024 Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group
  • February 27, 2024 Launch of Radicava® for the Treatment of ALS in Brazil～First successful launch by a partner in global expansion～
  • February 20, 2024 Application for Additional Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug
  • February 6, 2024 Pipeline ― State of New Product Development
  • January 29, 2024 Transfer of Three Marketed Products in Japan
  • January 26, 2024 Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund's third phase ―Targeting treatments for infectious diseases that burden the developing world―
  • January 23, 2024 Co-promotion of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
  • December 21, 2023 Execution of Share Transfer Agreement on Overseas Joint Venture Subsidiary
  • December 7, 2023 The mechanism of intracellular glucose uptake of SGLT2 was elucidated by Cryo-electron Microscopy analysis in a joint study with the University of Tokyo Published in Nature Structural & Molecular Biology
  • November 30, 2023 Launch of UPLIZNA® for Neuromyelitis Optica Spectrum Disorder in Taiwan
  • November 8, 2023 Mitsubishi Tanabe Pharma Corporation Entered into License Agreement with Kynexis for Neuropsychiatric Drug Candidate “MT-5356”
  • November 7, 2023 Sustainability Information
  • November 1, 2023 Pipeline ― State of New Product Development
  • October 25, 2023 A Global Phase 3 Clinical Trial of MT-2111 in Combination with Rituximab has been started in Japan
  • October 18, 2023 MT-2111 in Phase 2 part of Phase 1/2 Clinical Trial in Diffuse Large B-cell Lymphoma in Japan
  • October 4, 2023 Merger of Wholly Owned Subsidiary
  • September 27, 2023 The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs with novel mechanisms of action conducted by Mitsubishi Tanabe Pharma and a malaria research institution
  • August 2, 2023 Pipeline ― State of New Product Development
  • August 1, 2023 Global, Phase 3b study of Oral Edaravone in ALS
  • July 31, 2023 Launch of REMLEAS® capsules 40mg for Treatment of Tardive Dyskinesia in three ASEAN countries
  • June 16, 2023 MPH was Selected for AMED's Strengthening Program for Pharmaceutical Startup Ecosystem Initiative
  • June 12, 2023 New Launch of Mounjaro® 7.5mg/10mg/12.5mg/15mg Ateos®, the World's First Sustained Release GIP/GLP-1 Receptor Agonist Full Lineup Now Available
  • May 31, 2023 AnGes filed for approval of its HGF gene therapy product Collategene® for the first time since the introduction of the conditional/time-limited authorization system for regenerative medicine products
  • May 12, 2023 Pipeline ― State of New Product Development
  • May 11, 2023 RADICAVA® Oral Suspension Approved in Switzerland for the Treatment of ALS
  • April 18, 2023 New launch of Mounjaro® 2.5mg/5mg Ateos®, the world's first sustained release GIP/GLP-1 receptor agonist
  • April 17, 2023 For the Treatment of ALS, Edaravone RADICUT® Oral Suspension 2.1% Now Available in Japan
  • April 11, 2023 Support for the Earthquake Victims in Turkey and Syria
  • March 27, 2023 Anti-cytomegalovirus chemotherapeutic agent "Valixa® Dry Syrup 5000mg" Approved for the indication of symptomatic congenital cytomegalovirus infection in Japan
  • March 27, 2023 Approval of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
  • March 20, 2023 Notification of Application for Additional Dosage Form of SGLT2 inhibitor CANAGLU® OD Tablets 100 mg
  • February 28, 2023 Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group
  • February 16, 2023 Mitsubishi Chemical Group ― Notice on Revision to Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2023
  • February 14, 2023 Mitsubishi Chemical Group ― Notice of Award for the Arbitration Filed against Mitsubishi Tanabe Pharma Corporation, a Consolidated Subsidiary
  • February 7, 2023 Pipeline ― State of New Product Development
  • February 3, 2023 Overseas Consolidated Subsidiary, Medicago to Cease Operations
  • January 26, 2023 Mitsubishi Chemical Group Announces New Group Concept (Purpose, Slogan, Our Way)
  • January 20, 2023 Personnel Changes of the Mitsubishi Chemical Group
  • January 10, 2023 Announcement of Positive Results from the Phase 3 Clinical Trials of Parkinson's Disease Drug Candidate ND0612
  • December 23, 2022 For Treatment of ALS, Edaravone RADICUT® Oral Suspension 2.1% Approved in Japan
  • November 24, 2022 GARDP and Mitsubishi Tanabe Pharma Corporation announce partnership in search for new antibiotics
  • November 21, 2022 Sustainability Information
  • November 9, 2022 RADICAVA® Oral Suspension Approved in Canada for the Treatment of ALS
  • November 8, 2022 Pipeline ― State of New Product Development
  • October 17, 2022 Inebilizumab has received import and marketing permission in Taiwan for Neuromyelitis Optica Spectrum Disorder
  • September 26, 2022 Approval of Mounjaro, the world's first sustained release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes in Japan
  • August 5, 2022 Please beware of “spoofing e-mails, messages, etc.” that impersonate executives of Mitsubishi Tanabe Pharma Corporation (MTPC).
  • August 3, 2022 Pipeline ― State of New Product Development
  • July 21, 2022 Notice of Termination of the Recombinant Human Serum Albumin Business
  • July 13, 2022 Humanitarian Donation to Ukraine
  • July 7, 2022 Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide”
  • June 30, 2022 Anti-cytomegalovirus chemotherapeutic agents "Valixa® Dry Syrup 5000mg" Notification of application for additional indication of symptomatic congenital cytomegalovirus infection in Japan
  • June 21, 2022 CANAGLU® Tablets 100mg Approved for the Indication of Chronic Kidney Disease Complicated with Type 2 Diabetes Mellitus in Japan
  • June 16, 2022 RADICAVA ORS now available in U.S. for treatment of ALS
  • June 1, 2022 Launch of DYSVAL® capsules 40mg for Treatment of Tardive Dyskinesia in Japan for the treatment of ALS
  • May 13, 2022 Pipeline ― State of New Product Development
  • May 13, 2022 New Japan-originated ALS treatment option available to patients in the U.S.―FDA approval of RADICAVA ORS® for the treatment of ALS
  • May 13, 2022 Financial Information for FY2021
  • April 27, 2022 Announcement of Organizational Changes and Personnel Changes of Mitsubishi Chemical Holdings Group
  • April 25, 2022 Swissmedic has accepted the filling for a New Oral Edaravone Formulation for the treatment of ALS
  • April 11, 2022 Marketing Authorization Application of Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine (BK1310/MT-2355)
  • April 4, 2022 Long-Term Safety Profile from Phase 2b Clinical Trials of Parkinson's Disease Drug Candidate (ND0612) Presents at 2022 American Academy of Neurology Annual Meeting
  • April 1, 2022 One Company, One Team
  • March 28, 2022 Regulatory Approval of DYSVAL®capsules 40mg for Treatment of Tardive Dyskinesia in Japan
  • March 14, 2022 Submission of Oral Edaravone Formulation, MT-1186 New Drug Application in Japan for the Treatment of ALS
  • February 25, 2022 Progress of Innovative Drug Discovery Research Collaboration with HitGen
  • February 24, 2022 COVID-19 vaccine, "COVIFENZ®"(MT-2766) has been approved in Canada.
  • February 24, 2022 Organizational Changes and Personnel Changes of Mitsubishi Chemical Holdings Group
  • February 3, 2022 Financial Information for Q3 of FY2021
  • February 3, 2022 Pipeline ― State of New Product Development
  • February 2, 2022 Regulatory Approval of Cariprazine (MP-214) for Bipolar Disorder in Singapore
  • January 18, 2022 Mitsubishi Tanabe Pharma Corporation Enters into Exclusive License Agreement with ADC Therapeutics to Develop and Commercialize Loncastuximab Tesirine, Anti-CD19 Antibody Drug Conjugate ("ADC"), for Cancer in Japan
  • January 13, 2022 FDA Acceptance of New Drug Application for Oral Edaravone Formulation for the Treatment of ALS
  • January 7, 2022 Personnel Changes at Mitsubishi Chemical Holdings Group
  • December 22, 2021 Tianjin Tanabe and Suzuken (Shenzhen) join hands to promote TENELIA in China
  • December 17, 2021 MT-2766, the world's first plant-based COVID-19 vaccine candidate Application for approval was submitted in Canada.
  • December 10, 2021 Global Phase 3 Safety Study Results of Investigational Oral Edaravone MT-1186 in the treatment of ALS
  • December 7, 2021 MT-2766, Adjuvanted COVID-19 Vaccine Candidate, Showed Positive Efficacy and Safety Results in Phase 3 Study Conducted in an Environment Dominated by the Variants
  • December 7, 2021 Sustainability Information
  • December 3, 2021 Co-promotion agreement for VMAT2 inhibitor MT-5199 in Japan with Janssen Pharmaceutical K.K.
  • November 2, 2021 Financial Information for Q2 of FY2021
  • November 2, 2021 Pipeline ― State of New Product Development
  • October 20, 2021 Transfer of Urso API Manufacturing Business
  • October 8, 2021 Top-line data of J-KINECT Study, Phase 2/3 study in Japan of VMAT2 inhibitor MT-5199 in TD, presented at the 31st annual meeting of the Japanese Society of Clinical Neuropsychopharmacology
  • September 30, 2021 Start of a Japanese Clinical Study of MT-2766, Adjuvanted COVID-19 Vaccine Candidate
  • September 8, 2021 Phase 2 Trial of MT-3921 Initiated for Treatment of Spinal Cord Injury
  • August 5, 2021 Inebilizumab has been approved in South Korea for Neuromyelitis Optica Spectrum Disorder
  • August 4, 2021 Application for approval of CANAGLU® Tablets 100mg for the indication of chronic kidney disease with type 2 diabetes mellitus in Japan
  • August 4, 2021 Financial Information for Q1 of FY2021
  • August 4, 2021 MT-3921 Granted FDA Fast Track Designation for Treatment of Spinal Cord Injury
  • August 4, 2021 Pipeline ― State of New Product Development
  • July 1, 2021 Strengthen the Lineup of ALS Treatments in the U.S.EXSERVANTM (RILUZOLE) IS NOW AVAILABLE IN THE U.S. FOR THE TREATMENT OF ALS
  • June 18, 2021 Launch of TENELIA® OD Tablet for Type 2 Diabetes Mellitus ―Toward further convenience and improvement of Medication Compliance of DPP-4 inhibitors
  • June 1, 2021 Launch of UPLIZNA® for I.V. Infusion 100mg as a new option for the treatment of Neuromyelitis Optica Spectrum Disorder in Japan
  • May 25, 2021 Establishment of AI Technologies for Drug Screening To Accelerate Data-Driven Drug Discovery
  • May 19, 2021 Initiatives Against COVID-19 in Canada - Achieved Positive Interim Phase 2 Results for adjuvanted COVID-19 vaccine candidate -
  • May 12, 2021 Discontinuation of the Development of Nucleic Acid Products "MT-5745 (STNM01)" for Ulcerative Colitis and an Impairment Loss (non-recurring item)
  • May 12, 2021 Financial Information for FY2020
  • May 12, 2021 Pipeline ― State of New Product Development
  • April 26, 2021 Initiatives Against COVID-19 in Canada - Health Canada Initiates the Review of the Rolling Submission for COVID-19 VLP Vaccine Candidate -
  • April 22, 2021 Notification of Marketing Authorization Application of Valbenazine (MT-5199) for the Treatment of Tardive Dyskinesia in Japan
  • April 8, 2021 Mitsubishi Tanabe and Mineralys entered into the exclusive License Agreement for a cardiovascular agent “MT-4129” and FDA Accepts IND Application
  • March 31, 2021 Phase -2 Clinical Trial of MT-7117 Initiated in the U.S., Canada, and Europe for the Rare Disease, Diffuse Cutaneous Systemic Sclerosis (dcSSc)
  • March 31, 2021 Mitsubishi Tanabe Pharma Wins Patent Infringement Lawsuit of Canagliflozin Hydrate in the U.S. District Court
  • March 31, 2021 The Global Health Innovative Technology Fund provides grant to Mitsubishi Tanabe Pharma and DNDi for Chagas disease and leishmaniasis drug discovery ～Targeting treatments for infectious diseases that impact people in developing countries～
  • March 23, 2021 Manufacturing and Marketing Approval of UPLIZNA® for I.V. Infusion 100mg for the Treatment of Neuromyelitis Optica Spectrum Disorder in Japan
  • March 17, 2021 Initiatives Against COVID-19 in Canada - Initiate Phase 3 Portion of Phase 2/3 Clinical Trials and Fast Track Designation Granted by FDA -
  • March 3, 2021 Formulation of MISSION, VISION 30 and Medium-Term Management Plan 21–25 -Creating hope for all facing illness.-
  • March 3, 2021 Establish NeuroDiscovery Lab in the Boston Area to Strengthen the Discovery of Drug Targets for the Central Nervous System Disorders
  • February 26, 2021 Canagliflozin (TA-7284) has been approved in Taiwan For Diabetic Nephropathy
  • February 3, 2021 Financial Information for Q2 of FY2020
  • February 3, 2021 Results of J-KINECT Study,Phase 2/3 study in Japan of VMAT2 inhibitor MT-5199 in tardive dyskinesia
  • February 3, 2021 Pipeline ― State of New Product Development
  • January 26, 2021 Mitsubishi Tanabe Pharma and Pharma Foods International Enter into an Exclusive Licensing Agreement for a New Therapeutic Antibody to treat Autoimmune Diseases
  • January 18, 2021 Mitsubishi Tanabe Pharma and TAKEDA Share Internal Experimental Data to Accelerate Data-Driven Drug Discovery
  • January 14, 2021 Notice of the Arbitral Award on the License Agreement with Kolon Life Science
  • November 16, 2020 Initiatives Against COVID-19 in Canada - Initiate Phase 2/3 Clinical Trials of VLP Vaccine Candidate -
  • November 11, 2020 Initiatives Against COVID-19 in Canada - Phase 1 Results for COVID-19 Vaccine Candidate -
  • November 4, 2020 Changes in Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease Development Plan and an Impairment Loss (Non-recurring Items)
  • November 4, 2020 Financial Information for Q1 of FY2020
  • November 4, 2020 Pipeline ― State of New Product Development
  • October 26, 2020 Sustainability Information
  • October 26, 2020 Initiatives Against COVID-19 in Canada - Reached Agreements with Government of Canada to Receive Development Funding and Supply VLP Vaccine -
  • October 8, 2020 Canagliflozin (TA-7284) has been approved in Indonesia for Type2 Diabetes Mellitus
  • August 27, 2020 The website has been redesigned.
  • August 26, 2020 Launch of VAFSEO®, for the treatment of renal anemia (HIF-PH inhibitor) in Japan
  • August 4, 2020 Financial Information for Q3 of FY2020
  • July 28, 2020 Clinical Trial Information
  • July 16, 2020 As the First ALS Treatment in Indonesia RADICAVA has been approved first in ASEAN countries
  • July 15, 2020 Initiatives Against COVID-19 in Canada - Initiated Phase 1 Clinical Trials of VLP Vaccine Candidate
  • July 8, 2020 Announcement of Collaboration between Medicago and GSK in the Development of COVID-19 Vaccine and the Start of Phase 1 Clinical Trials
  • June 29, 2020 Manufacturing and Marketing Approval of VAFSEO® Tablets (HIF-PH inhibitor, vadadustat) for renal anemia in Japan
  • June 26, 2020 Notification of Marketing Authorization Application for Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder in Japan
  • June 15, 2020 Start of a Phase 3 Clinical Trial of MT-7117 for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
  • May 25, 2020 Regulatory Approval of Thailand for Marketing Teneligliptin (MP-513)， a treatment agent for type 2 diabetes mellitus
  • May 18, 2020 Initiatives Against COVID-19 in Canada -Intermediary Results of VLP Vaccine Pre-clinical Study pdf （353KB）
  • May 18, 2020 Co-marketing agreement concerning Vadadustat (MT-6548) for renal anemia in Japan with Fuso Pharmaceutical in hemodialysis and peritoneal dialysis patients
  • May 13, 2020 Financial Information for FY2019
  • April 28, 2020 Notification of Changes in the U.S. Development Plan of VLP Vaccine for Seasonal Influenza Prevention (MT-2271) and an Impairment Loss (Non-recurring Items)
  • April 1, 2020 SIMPONI® self-injection formulation for ulcerative colitis now reimbursed through NHI
  • March 25, 2020 STELARA® (ustekinumab) Now Approved for the Treatment of Adults with Moderate-to-Severe Ulcerative Colitis in Japan
  • March 12, 2020 Medicago, a subsidiary in Canada, is tackling with COVID-19, coronavirus
  • February 26, 2020 Announcement Concerning Delisting of the Company Shares
  • February 25, 2020 Change in Representative Director
  • February 5, 2020 Mitsubishi Tanabe Pharma expands domestic co-promotion framework for STELARA®. An application for an additional indication has been filed for ulcerative colitis, which will be included in co-promotion activities.
  • January 17, 2020 Announcement of Mitsubishi Chemical Holdings Corporation’s Decision to Make a Demand for Sale of Our Shares, and Our Approval of that Demand for Sale of Our Shares and Delisting of Our Shares
  • January 14, 2020 Change in Representative Director
  • January 8, 2020 Announcement Concerning Results of the Tender Offer of Our Shares by Mitsubishi Chemical Holdings Corporation which is Our Controlling Shareholder
  • November 27, 2019 Launch of Alesion® LX Ophthalmic Solution 0.1% in Japan pdf （382KB）
  • November 25, 2019 Mitsubishi Tanabe Pharma Announces the Start of a Phase 3 Clinical Trial using Oral Suspension of Edaravone for ALS pdf （412KB）
  • November 18, 2019 Announcement of Mitsubishi Tanabe Pharma Corporation’s Opinion RegardingTender Offer for Shares in Mitsubishi Tanabe Pharma Corporation by the Controlling Shareholder Mitsubishi Chemical Holdings Corporation, and Recommendation to Tender Shares pdf （1,034KB）
  • November 18, 2019 To Our Shareholders: Notice of Statement of Opinion Regarding Tender Offer for Mitsubishi Tanabe’s Shares by Mitsubishi Chemical Holdings Corporation. and Recommendation to Tender Shares pdf （48KB）
  • November 11, 2019 Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) pdf （367KB）
  • November 11, 2019 HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019 pdf （466KB）
  • October 25, 2019 Revision to the First Half Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020 pdf （89KB）
  • October 25, 2019 Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019 pdf （433KB）
  • October 9, 2019 Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions pdf （61KB）
  • October 2, 2019 Notification of acceptance of the New Drug Submission for Scientific Review of VLP Seasonal Influenza Vaccines（MT-2271）by Health Canada pdf （519KB）
  • September 30, 2019 Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund ～Targeting treatments for infectious diseases that burden the developing countries～ pdf （378KB）
  • September 24, 2019 NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in China pdf （482KB）
  • September 20, 2019 Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion® Ophthalmic Solution 0.05% and Alesion® LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co.; Ltd. pdf （407KB）
  • September 18, 2019 Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index
  • September 17, 2019 Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in Brazil pdf （43KB）
  • September 4, 2019 Notice regarding the launch of Collategene® intramuscular injection 4 mg, an HGF gene therapy product
  • August 28, 2019 The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s disease
  • August 8, 2019 PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US IND
  • August 8, 2019 Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand)
  • August 7, 2019 NMPA approved Japan-originated ALS treatment Edaravone in China
  • August 6, 2019 Commencement of R&D of Gene Therapy Product for Hemophilia B
  • July 23, 2019 Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemia
  • May 30, 2019 Withdrawal of Marketing Authorization Application of edaravone for ALS in the European Union
  • May 29, 2019 Launch of SIMPONI® Subcutaneous Injection 50mg Autoinjector
  • April 26, 2019 Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseases
  • April 26, 2019 Medicago Awarded "Best New Vaccine Technology/Platform" at the World Vaccine Congress
  • April 24, 2019 Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019
  • April 15, 2019 For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in China
  • April 11, 2019 Notice Regarding Reorganization of Research, Production, and Technology Bases
  • March 28, 2019 The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institution
  • March 26, 2019 AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
  • March 20, 2019 Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative Office
  • March 12, 2019 Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKD
  • February 28, 2019 Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA® in China
  • February 20, 2019 Mitsubishi Tanabe Pharma Received Notice of Request for Arbitration
  • February 14, 2019 FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid Tumors
  • February 12, 2019 First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care App
  • February 6, 2019 Swissmedic approves RADICAVA, Japan-originated ALS treatment
  • February 4, 2019 Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.
  • December 11, 2018 HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
  • December 10, 2018 Conduct a study to identify and measure specific biomarkers in ALS - we will strive to deliver a beneficial therapy option to patients -
  • November 19, 2018 Notice Regarding Revision of Medium-Term Management Plan 16-20: Open Up the Future
  • November 15, 2018 Mitsubishi Tanabe Pharma to present New data on Investigational Oral Suspension of Edaravone for ALS at 29th International Symposium on ALS/MND
  • October 22, 2018 Strategic Research Collaboration for the Development of Innovative Antibody Drug to Treat Autoimmune Diseases pdf （238KB）
  • October 9, 2018 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS®", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
  • October 5, 2018 For the ALS patients in Canada, we hope to deliver Japan-originated ALS treatment ―Health Canada approves RADICAVA™ (edaravone) for the treatment of ALS
  • September 26, 2018 Company name changes of our oversea subsidiaries
  • September 18, 2018 Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index
  • July 27, 2018 Mitsubishi Tanabe Pharma's MT-7117 Receives U.S. FDA Fast Track Designation for the Investigational Treatment of Patients with the Ultra-Rare Disease, Erythropoietic Protoporphyria
  • July 19, 2018 Mitsubishi Tanabe Pharma Receives The 43rd (FY2018) Inoue Harushige Prize ― A challenge for the new drug against amyotrophic lateral sclerosis (ALS), research and development of edaravone―
  • July 2, 2018 Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science” - Toward the Innovative Drug Discovery for refractory Neurological Diseases -
  • July 2, 2018 Open Call for Applicants for Researcher-Initiated Clinical Research Funds - We Ensure Transparency and Support Investigator-Initiated Research Based on Japan's Clinical Research Act -
  • June 28, 2018 Mitsubishi Tanabe Pharma and Janssen Pharmaceutical　K.K. update co-promotion framework for STELARA®, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA® to treat adults with Crohn’s disease in Japan
  • June 14, 2018 TFDA approves Clenafin/Jublia for the treatment of Onychomycosis in Taiwan
  • May 30, 2018 Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development―Start of collaborative/competitive drug discovery research by three academic institutions and three pharmaceutical companies
  • May 28, 2018 For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―EMA accepts our filing for Edaravone to treat ALS
  • May 18, 2018 Canagliflozin (Antidiabetic agent) wins The Technology Award Grand Prize from the Japan Chemical Industry Association (JCIA)
  • April 10, 2018 Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life Science
  • April 10, 2018 To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in Canada
  • March 26, 2018 Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
  • March 6, 2018 Name Change of our Singapore Subsidiary
  • March 1, 2018 Mitsubishi Tanabe Pharma Group started marketing CANAGLU® Tablets 100mg, a treatment agent for type 2 diabetes mellitus in Taiwan
  • February 28, 2018 Valixa® Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrup
  • January 23, 2018 Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatment
  • January 16, 2018 Approval in China Received for Additional Novastan® Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical Market
  • January 11, 2018 Launch of "KREMEZIN® Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―
  • December 20, 2017 Update of Previous Disclosure ― License Agreement with Kolon Life Science on Invossa®
  • December 13, 2017 Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS
  • November 22, 2017 Launch of Rupafin® tablets in Japan ―Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)
  • November 8, 2017 Distribution Agreement for Clenafin/Jublia in Taiwan
  • November 1, 2017 Notice Regarding Mitsubishi Tanabe Pharma’s Acquisition of Stelic Institute & Co., Inc. Securing Nucleic Acid Pharmaceuticals of Inflammatory bowel disease for Future Launch in the U.S.
  • November 1, 2017 Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia
  • October 24, 2017 Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2018
  • October 18, 2017 Completion of Acquisition of NeuroDerm (100% Ownership)
  • October 11, 2017 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library -Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innov
  • October 2, 2017 Completion of Transfer of Shares of Generic Drugs Subsidiary (Update of Previous Disclosure)
  • September 29, 2017 Organizational Change and Personnel Change
  • September 27, 2017 Notice regarding acquisition of manufacturing and sales approval for Rupafin® tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)
  • September 27, 2017 Notice of the Start of Phase 3 Clinical Study of VLP Seasonal Influenza Vaccine
  • September 13, 2017 Approval of Mitsubishi Tanabe Pharma’s Acquisition of NeuroDerm at NeuroDerm’s General Meeting of Shareholders
  • September 7, 2017 Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent-Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets-
  • September 4, 2017 Start of Operations of Vaccine Manufacturing Joint Venture: BIKEN Co., Ltd.
  • August 17, 2017 Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis pdf （340KB）
  • August 9, 2017 RADICAVA to treat ALS now available in U.S.
  • July 27, 2017 Notice regarding the initiation of a phase 2/3 clinical trial in Japan for tardive dyskinesia patients for VMAT2 inhibitor MT-5199
  • July 24, 2017 Mitsubishi Tanabe Pharma to Acquire NeuroDerm Ltd.
  • July 3, 2017 Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug ―Application approved in Japan for CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent -Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets-
  • June 30, 2017 Conclusion of Agreement on Absorption-Type Company Split of Generic Drugs and Part of the Long-Listed Products Business
  • June 20, 2017 Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District Court
  • June 1, 2017 Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase ―Targeting treatments for infectious diseases that burden the developing world―
  • May 18, 2017 Approval for partial change in administration / dosage for Crohn’s disease for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody
  • May 16, 2017 Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALS
  • May 10, 2017 Differences Between Non-Consolidated Actual Results for FY2015 and FY2016
  • May 10, 2017 Notice of Dividend of Retained Earnings
  • May 10, 2017 Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin Preparation
  • May 9, 2017 Establishment of Vaccine Manufacturing Joint Venture: BIKEN CO.,Ltd.
  • May 8, 2017 New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA™ (edaravone) for the treatment of ALS
  • April 26, 2017 Introduction of Performance-Linked Stock Compensation Plan for Board Directors
  • April 24, 2017 Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU® Tablets 100mg, a treatment agent for type 2 diabetes mellitus
  • April 17, 2017 Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN region
  • March 30, 2017 Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI® subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF α
  • March 29, 2017 Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA® Tablets, a selective DPP-4 inhibitor, and CANAGLU® Tablets, an SGLT2 inhibitor
  • March 28, 2017 Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of Subsidiary
  • February 3, 2017 Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA® for an indication of Crohn’s disease
  • January 27, 2017 Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303
  • December 9, 2016 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND pdf （104KB）
  • November 7, 2016 Basic Agreement on the Establishment of a Joint Venture
  • November 1, 2016 Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritis
  • October 25, 2016 Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2017
  • October 5, 2016 Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world―
  • October 4, 2016 Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine Tablets
  • September 29, 2016 Regarding Edaravone Access in U.S. pdf （48KB）
  • September 6, 2016 Application for partial change in administration/dosage for Crohn's disease for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody
  • August 30, 2016 FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS
  • August 26, 2016 Valixa® Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients
  • August 23, 2016 Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA® Tablets and SGLT2 inhibitor CANAGLU® Tablets -
  • June 22, 2016 Regarding Nomination Committee and Compensation Committee pdf （109KB）
  • June 20, 2016 Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States
  • June 6, 2016 Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund
  • May 13, 2016 Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in Psoriasis
  • May 13, 2016 Corrections with respect to “Summary of Financial Results for year ended March 31, 2016”　(Japan GAAP) (Consolidated) pdf （51KB）
  • May 11, 2016 Notice of Dividend of Retained Earnings
  • April 27, 2016 Change of Representative Director, Director and Corporate Auditor
  • April 20, 2016 Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting pdf （301KB）
  • April 4, 2016 MT Pharma Singapore Pte. Ltd. Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in Singapore
  • March 29, 2016 Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
  • March 22, 2016 Valixa® Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based Application
  • March 10, 2016 Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi® subcutaneous injection 50 mg syringe (generic name: golimumab)
  • February 23, 2016 Mitsubishi Tanabe Pharma Enhances Operations in the United States
  • February 3, 2016 Notice Regarding Results of Early Retirement Program
  • December 21, 2015 Remicade® for I.V. Infusion 100 Approval of Additional Indication for Kawasaki Disease World First Biologic Treatment
  • December 21, 2015 RADICUT® inj. 30mg and RADICUT® Infusion inj. 30mg An import and Marketing Permission for ALS in South Korea
  • December 15, 2015 Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
  • November 30, 2015 Formulation of the Medium-Term Management Plan 16-20: Open Up the Future
  • November 20, 2015 Announcement of an approval for an additional indication for the Anti-depressant, Lexapro® Tablets 10 mg in Japan
  • October 30, 2015 Notice Regarding Implementation of Early Retirement Program
  • October 30, 2015 Medicago Engaged by the Canadian Government Produce Ebola Monoclonal Antibodies
  • October 2, 2015 Mitsubishi Tanabe Pharma and Regeneron Conclude Collaboration Agreement for Fasinumab, NGF Antibody
  • September 30, 2015 Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016
  • September 23, 2015 MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer
  • September 17, 2015 Notice Regarding Worldwide Patent and Know-how Transfer, Excluding Japan and Certain Other Territories in Asia, for TA-8995 (CETP inhibitor), a Treatment Agent for Dyslipidemia
  • September 15, 2015 MT-4666 in Alzheimer’s Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan
  • September 9, 2015 Biogen and Mitsubishi Tanabe Pharma Conclude a License Agreement on MT-1303, a Therapeutic Agent for Autoimmune Diseases
  • August 24, 2015 Approval of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for Additional Indications for Entero-Behcet's Disease, Neuro-Behcet's Disease, and Vasculo-Behcet's Disease
  • July 27, 2015 Organizational Restructuring
  • July 10, 2015 Application Filed for a Partial Change in Dosage and Usage of REMICADE® for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, in Psoriasis
  • June 26, 2015 RADICUT® inj. 30mg and RADICUT® BAG for I.V. Infusion 30mg Mitsubishi Tanabe Pharma Corporation receives approval for additional indication for Amyotrophic Lateral Sclerosis (ALS) in Japan
  • May 26, 2015 Approval for Additional Pediatric Indications in Japan Received for TALION® Tablets and TALION® OD Tablets, Anti-Allergic Agents
  • May 22, 2015 Mitsubishi Tanabe Pharma provides Compound Library to Screening Program of Global Health Innovative Technology Fund
  • May 15, 2015 Application filed for REMICADE? for I.V. Infusion 100, an anti-human TNFα monoclonal antibody, for an additional indication for Kawasaki disease pdf （141KB）
  • May 8, 2015 Notice of Dividend of Retained Earnings
  • April 1, 2015 Execution of License Agreement on VMAT2 Inhibitor NBI-98854
  • February 25, 2015 Medicago Develops Alternative Production Process for Ebola Antibodies Contract concluded with U.S. government
  • February 25, 2015 Reorganization of research bases in Japan
  • February 6, 2015 Completion of Construction of the New Head Office Building
  • January 29, 2015 -Increasing Production Capacity to Meet Growing Asian Pharmaceutical Markets -Completion of New Manufacturing FacilityTianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia
  • December 18, 2014 Reorganization of the U.S. Affiliates to Accelerate the U.S. Operations Expansion
  • November 28, 2014 Notice regarding conclusion of the final agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd.
  • November 13, 2014 Application filed for additional indication for ALS for RADICUT® inj. 30mg and RADICUT BAG for I.V. Infusion 30mg
  • November 6, 2014 Supporting “good blood glucose control” in Japanese patients with diabetes joint promotion with Johnson & Johnson K.K. Medical Company
  • October 30, 2014 Applications filed for REMICADE® for I.V. Infusion 100, an anti-human TNFα monoclonal antibody, for additional indications for entero-Behcet’s disease, neuro-Behcet’s disease, and vasculo-Behcet’s disease
  • October 21, 2014 Revisions to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2015
  • September 19, 2014 TELAVIC® 250mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2
  • September 2, 2014 Launch of CANAGLU® Tablets 100mg A SGLT2 inhibitor for Type2 Diabetes Mellitus
  • August 20, 2014 MITSUBISHI TANABE PHARMA CORPORATION AND ASTRAZENECA ANNOUNCE RESEARCH COLLABORATION IN DIABETIC NEPHROPATHY
  • July 4, 2014 Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg
  • June 30, 2014 Notice regarding conclusion of a basic agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd.
  • June 30, 2014 Notice Regarding Voluntary Adoption of International Financial Reporting Standards (IFRS)
  • June 16, 2014 Positive Phase 3 Results of Canagliflozin in Japanese Patients with Type 2 Diabetes at American Diabetes Association
  • May 30, 2014 Name Change of Group Company in China
  • May 29, 2014 Announcement of Merger (Simplified Merger and Short form Merger) of Consolidated Subsidiary
  • May 28, 2014 Name Change of Consolidated Subsidiaries in Europe
  • April 23, 2014 Change of Representative Directors and Personnel
  • February 6, 2014 Change of Representative Directors
  • February 3, 2014 MT-4666 in Alzheimer’s DiseaseStart of Global Phase 3 Clinical Trial Program, COGNITIV AD
  • January 16, 2014 TELAVIC® 250mg Tablets, Antiviral Application for additional Indication for Chronic Hepatitis C Genotype 2
  • December 20, 2013 TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy
  • September 30, 2013 Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law of Japan
  • September 25, 2013 Revision to 2Q Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2014
  • September 19, 2013 Mitsubishi Tanabe Pharma to Open Singapore Office
  • September 19, 2013 Notice Regarding Completion of Acquisition of Shares of Medicago, Inc., a Pharmaceutical Company Based in Canada, Which Has Become a Subsidiary of Mitsubishi Tanabe Pharma
  • September 9, 2013 Tanabe Indonesia to Construct New Production Facility in Indonesia
  • August 8, 2013 Notice Regarding Arbitration Award in Dispute with Janssen Biotech, Inc.
  • August 6, 2013 Tianjin Tanabe Seiyaku to Construct New Production Facility in China
  • August 1, 2013 Notice regarding the reorganization of Mitsubishi Tanabe Pharma Factory Ltd.'s domestic production sites and the conclusion of a basic agreement regarding the transfer of its Ashikaga Plant
  • July 12, 2013 Notice regarding the acquisition of Medicago Inc.
  • June 27, 2013 VIVUS gains MAA approval for TA-1790 in the EU
  • June 14, 2013 Approval for Additional Indication for Atrial Fibrillation (Tachycardiac ) MAINTATE® Tablets: Selective β1 Blocker
  • May 27, 2013 New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes
  • April 30, 2013 Change of Directors
  • April 3, 2013 Launch of BindRen® for Treatment of Hyperphosphatemia in Germany and Austria
  • April 1, 2013 Transfer of Tanabe Europe’s shares
  • April 1, 2013 U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes
  • February 28, 2013 Approval for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
  • February 26, 2013 TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Application for Partial Change in Indications for Combination Therapy
  • February 21, 2013 Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
  • January 29, 2013 BindRen® Granted Marketing Authorization in Europe for Treatment of Hyperphosphatemia
  • October 26, 2012 Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine
  • October 19, 2012 Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd.
  • October 10, 2012 Outcome of Global Phase III (EPPIC) Studies
  • October 1, 2012 Outsourcing of Logistics Operations
  • September 28, 2012 Application for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
  • September 20, 2012 Launch of "Simponi®”, a human TNFα monoclonal antibody in Indonesia
  • September 13, 2012 MAINTATE® Tablets: Selective β1 AntagonistNotice regarding application for additional indication for chronic atrial fibrillation
  • August 31, 2012 Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
  • August 31, 2012 Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation
  • August 28, 2012 Launch of TENELIA® 20mg TabletsA DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
  • July 23, 2012 Launch of Tranquilizer, DEPAS® TABLETS 0.25 mg
  • July 6, 2012 Launch of Argatroban, a Selective Antithrombin Agent, in UK
  • June 29, 2012 Marketing and Manufacturing Approval Received for TENELIA® 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
  • June 6, 2012 Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan
  • June 1, 2012 Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism
  • May 15, 2012 Notice Regarding Transfer of Fine Chemical Operations
  • May 9, 2012 Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Indonesia
  • May 8, 2012 Notice of Dividend of Retained Earnings
  • May 8, 2012 New Organization in Plasma Fractionation Operations Establishment of “Japan Blood Products Organization”
  • May 8, 2012 Remicade® for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody A New Option to Shorten Infusion Time
  • May 8, 2012 Remicade® for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody Lifting of Condition on Approval for Psoriasis
  • May 7, 2012 VIVUS gains NDA approval for TA-1790 in the US
  • March 29, 2012 Launch of "SIMPONI™”, a human TNFα monoclonal antibody in Taiwan
  • March 21, 2012 “IMUSERA® Capsules 0.5mg” Multiple Sclerosis Treatment Agent Notice regarding revision of “warnings” and “important basic precautions” sections of prescribing information
  • March 7, 2012 Conclusion of Research Collaboration Agreement for Next-Generation Vaccines
  • March 6, 2012 Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan Companies conclude joint sales agreement for two treatments for type 2 diabetes mellitus - MP-513 and TA-7284
  • January 16, 2012 Conclusion of Licensing Agreement for Hib Vaccine
  • December 1, 2011 Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN® and LULLAN®
  • November 25, 2011 Launch of "IMUSERA® Capsules 0.5mg" Japan's First Oral Dosing Multiple Sclerosis Treatment with Novel Mode of Action
  • November 25, 2011 Launch of Antiviral Agent "TELAVIC® Tablets 250 mg" Novel Mode of Action for Chronic Hepatitis C Treatment
  • November 25, 2011 Approval of Additional Indication for MODIODAL® Tablets 100 mg a Sleep Disorder Treatment
  • November 18, 2011 Notice of postponement of integrating the plasma fractionation operations of the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation
  • October 31, 2011 Revision of Dividend of Retained Earnings and Year-end Dividend Forecast
  • October 17, 2011 Formulation of Medium-Term Management Plan 11-15 New Value Creation pdf （149KB）
  • October 17, 2011 ＜Presentation Material＞ pdf （3,942KB）
  • October 14, 2011 Toray, Mitsubishi Tanabe Pharma Reach North American License Agreement on Antipruritic Agent, TRK-820
  • September 26, 2011 Approval for "IMUSERA® Capsules 0.5mg" Japan's First Once-Daily Oral Dosing Multiple Sclerosis Treatment
  • September 26, 2011 Approval for TELAVIC® 250mg Tablet Novel Mode of Action for Chronic Hepatitis C Treatment
  • September 26, 2011 Approval for Additional Indication of Generalized Myasthenia Gravis Venoglobulin® IH 5% for Intravenous Injection, a Human Immunoglobulin Preparation Derived from Donated Plasma
  • September 15, 2011 Launch of "SIMPONI® (golimumab) Subcutaneous Injection 50mg Syringe" A Treatment of Rheumatoid Arthritis
  • September 1, 2011 New Drug Application Filed in Japan for MP-513 a Type 2 Diabetes Treatment
  • August 22, 2011 Mitsubishi Tanabe Pharma Prevails in U.S. Argatroban Patent Litigation
  • August 17, 2011 Remicade® for I.V. Infusion 100, Anti-Human TNF α Monoclonal-Antibody Approval for a Partial Change of Dosage and Usage in Crohn’s Disease
  • July 29, 2011 Revision to First Half and Full Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2012
  • July 21, 2011 The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro® 10mg
  • July 19, 2011 Notice Regarding a Business Suspension Order for the Ashikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd. and a Business Improvement Order for Mitsubishi Tanabe Pharma Corporation
  • July 1, 2011 Approval for "SIMPONI® Subcutaneous Injection 50mg Syringe (Generic Name: Golimumab)" for Treatment of Rheumatoid Arthritis
  • June 17, 2011 Notice of a basic agreement between the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation regarding the commencement of discussions about the integration of their plasma fractionation operations
  • June 2, 2011 AZANIN® Tablets 50mg, Immunosuppressant Approval for Additional Indication for Refractory Rheumatic Diseases
  • May 27, 2011 Launch of Anti-allergy Agent, Bepotastine Besilate in China and Indonesia
  • May 20, 2011 Approval for Additional Indication for selective β1 antagonist, MAINTATE® Tablets 0.625, 2.5, and 5 and Launch of MAINTATE® Tablets 0.625
  • May 20, 2011 Approval for Additional Indications for the Selective Antithrombin Agents, Novastan® HI Injection 10 mg/2mL and Slonnon® HI Injection 10 mg/2mL
  • May 20, 2011 Approval for Additional Indication of Anti-D Human Immunoglobulin I.M.1000-BENESIS (Dry anti-Rho(D) Immune Human Globulin)
  • May 10, 2011 Partial Amendment of the Articles of Incorporation
  • April 27, 2011 Change of Directors, and Organization
  • April 27, 2011 Summary of the Quality Control Incident
  • April 27, 2011 Partial Return of Executive Compensation
  • April 11, 2011 Impact of the Great East Japan Earthquake (3rd Notice)
  • March 30, 2011 Impact of the 2011 off the Pacific coast of Tohoku Earthquake (2nd Notice)
  • March 28, 2011 Novartis receives European Commission approval for FTY720, the first oral multiple sclerosis treatment for use in the EU
  • March 15, 2011 Impact of the 2011 off the Pacific coast of Tohoku Earthquake
  • March 14, 2011 Mitsubishi Tanabe Pharma Supports Japan Earthquake Relief Efforts
  • March 11, 2011 Open innovation laboratory for drug discovery and development by Mitsubishi Tanabe Pharma and Kyoto University -Basic and clinical research project for CKD drugs-
  • March 7, 2011 Transfer of Marketing Rights of 5 Long-term Listed Drugs to Tanabe Seiyaku Hanbai
  • January 28, 2011 Application Submitted in Japan for MP-424 a Novel Chronic Hepatitis C Treatment
  • January 28, 2011 Nycomed and Mitsubishi Tanabe Pharma to Terminate Collaborative Development of APTA-2217, Roflumilast for Treatment of Respiratory Diseases in Japanese Market
  • January 26, 2011 Notice Regarding Voluntary Recall of Three Drugs (Six Dosage Sizes)
  • January 11, 2011 Kremezin®, Drug for Chronic Renal Failure Transfer of Marketing Rights in Japan
  • December 21, 2010 Out-Licensing of Bepotastine Besilate for Ophthalmic Use to a South Korea pdf （11KB）
  • December 20, 2010 Application Submitted in Japan for FTY720, a Novel Multiple Sclerosis Treatment
  • December 14, 2010 Commencement of R&D Partnership with Anaphore for Atrimer™ Technology (Novel Trivalent Proteins)
  • December 1, 2010 Removal of Grace Period
  • October 29, 2010 Notice Regarding Change in the Number of Shares Constituting One Trading Unit and Partial Amendments to the Articles of Incorporation
  • October 27, 2010 Approval of additional indication of Venoglobulin® IH 5% I.V., human immunoglobulin G for the treatment of polymyositis and dermatomyositis
  • October 12, 2010 Launch New 1000 mg Dosage Formulations of Pasil® and Pazucross® Injectable New Quinolone Antibacterial Agents on October 13
  • October 4, 2010 Revision to First Half and Full Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2011
  • September 28, 2010 Novartis gains NDA approval for FTY720 in the US
  • August 18, 2010 Completes Post-Marketing Surveillance on All Patients with Refractory Uveoretinitis in Behcet's Disease REMICADE I.V. Drip Infusion Anti-TNFα Monoclonal Antibody 100
  • July 30, 2010 Selective β1 Receptor Blocker "Kerlong® Tablets 5mg/10mg" Transfer of Manufacturing, Marketing, and Distribution Rights
  • July 29, 2010 Revision to First Half Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2011
  • July 23, 2010 Approval for Partial Changes in Indications, Dosage and Usage, as well as New 1000 mg Dosage Formulation, for Injectable New Quinolone Antibacterial Agents, Pasil® and Pazucross®
  • July 1, 2010 GlaxoSmithKline and Mitsubishi Tanabe Pharma Corporation Terminates co-promotion of Adoair®, the combination drug for asthma and COPD
  • June 18, 2010 Approval of Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
  • June 18, 2010 Approval for Additional Indication of Ulcerative Colitis for Remicade I.V. Drip Infusion 100, Anti-Human TNF α Monoclonal-Antibody
  • June 16, 2010 Notice Regarding Submission of Business Improvement Plans
  • May 12, 2010 Change of Representative Directors, Directors, and Organization
  • May 12, 2010 Partial Return of Executive Compensation
  • April 13, 2010 Notice Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law
  • February 10, 2010 Tianjin Tanabe Seiyaku Receives ISO 14001 Certification
  • January 25, 2010 Mitsubishi Tanabe Pharma Supports Relief Efforts for Haiti Earthquake Disaster
  • January 20, 2010 Approval for Additional Indication of Psoriasis for Remicade® I.V. Drip Infusion 100, Anti-Human TNF-α Monoclonal-Antibody
  • January 19, 2010 Approval for New Dosage Form of RADICUT®, Cerebral Neuroprotectant "RADICUT® BAG for I.V. infusion 30mg"
  • January 7, 2010 Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in Japan

Tanabe Pharma issues its news to provide stakeholders with the latest information related to the Company. Information on products or drug candidates may be included, but is intended to provide for the media, etc. It is not intended for promotion, advertising or medical advice. Information is current as of the date of issue of the individual news. Please be advised that information may be outdated after that point.

VIEW ALL

  • header-content
  • header-content

  • CLOSE
  • MENU

Site Search

If you agree to the use of cookies, please click the "Agree" button.
If you do not agree, please do not use this site. For details, please refer to the following page.

Privacy Policy

Agree

URL
 

田辺ファーマ株式会社のサイトを離れます。よろしいですか？
（別ウィンドウが開きます）

You are leaving the Tanabe Pharma Corporation’s website.
(A new window will be opened.)

はい / O.K.
いいえ / Cancel
  • footer-content